» Articles » PMID: 35704747

Lessons from Acquired Natural Immunity and Clinical Trials to Inform Next-Generation Human Cytomegalovirus Vaccine Development

Overview
Journal Annu Rev Virol
Publisher Annual Reviews
Specialty Microbiology
Date 2022 Jun 15
PMID 35704747
Authors
Affiliations
Soon will be listed here.
Abstract

Human cytomegalovirus (HCMV) infection, the most common cause of congenital disease globally, affecting an estimated 1 million newborns annually, can result in lifelong sequelae in infants, such as sensorineural hearing loss and brain damage. HCMV infection also leads to a significant disease burden in immunocompromised individuals. Hence, an effective HCMV vaccine is urgently needed to prevent infection and HCMV-associated diseases. Unfortunately, despite more than five decades of vaccine development, no successful HCMV vaccine is available. This review summarizes what we have learned from acquired natural immunity, including innate and adaptive immunity; the successes and failures of HCMV vaccine human clinical trials; the progress in related animal models; and the analysis of protective immune responses during natural infection and vaccination settings. Finally, we propose novel vaccine strategies that will harness the knowledge of protective immunity and employ new technology and vaccine concepts to inform next-generation HCMV vaccine development.

Citing Articles

Immune surveillance of cytomegalovirus in tissues.

Mihalic A, Zeleznjak J, Lisnic B, Jonjic S, Juranic Lisnic V, Brizic I Cell Mol Immunol. 2024; 21(9):959-981.

PMID: 39134803 PMC: 11364667. DOI: 10.1038/s41423-024-01186-2.


Human Cytomegalovirus (HCMV) Genetic Diversity, Drug Resistance Testing and Prevalence of the Resistance Mutations: A Literature Review.

Grgic I, Gorenec L Trop Med Infect Dis. 2024; 9(2).

PMID: 38393138 PMC: 10892457. DOI: 10.3390/tropicalmed9020049.


Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth.

Wang H, Li L, Nelson C, Barfield R, Valencia S, Chan C NPJ Vaccines. 2024; 9(1):38.

PMID: 38378950 PMC: 10879498. DOI: 10.1038/s41541-024-00821-3.


Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine.

Hu X, Karthigeyan K, Herbek S, Valencia S, Jenks J, Webster H J Infect Dis. 2024; 230(2):455-466.

PMID: 38324766 PMC: 11326847. DOI: 10.1093/infdis/jiad593.


Modulation of Epstein-Barr-Virus (EBV)-Associated Cancers by Co-Infections.

Munz C Cancers (Basel). 2023; 15(24).

PMID: 38136285 PMC: 10741436. DOI: 10.3390/cancers15245739.


References
1.
Schleiss M . VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection. Curr Opin Mol Ther. 2009; 11(5):572-8. PMC: 3539801. View

2.
McLean C, Erturk M, Jennings R, Challanain D, Minson A, Duncan I . Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J Infect Dis. 1994; 170(5):1100-9. DOI: 10.1093/infdis/170.5.1100. View

3.
John S, Yuzhakov O, Woods A, Deterling J, Hassett K, Shaw C . Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. Vaccine. 2018; 36(12):1689-1699. DOI: 10.1016/j.vaccine.2018.01.029. View

4.
La Rosa C, Longmate J, Lacey S, Kaltcheva T, Sharan R, Marsano D . Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis. 2012; 205(8):1294-304. PMC: 3308906. DOI: 10.1093/infdis/jis107. View

5.
Tian M, Cheng C, Chen X, Duan H, Cheng H, Dao M . Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. Cell. 2016; 166(6):1471-1484.e18. PMC: 5103708. DOI: 10.1016/j.cell.2016.07.029. View